摘要
目的观察反应停联合VAD方案治疗难治及复发性多发性骨髓瘤的临床疗效并测定反应停治疗前后血清VEGF水平的变化。方法反应停剂量为400￣600mg/d,每5周联合VAD方案治疗难治及复发性多发性骨髓瘤28例。有效病例治疗前和治疗后12周测定血清中VEGF水平。结果总有效率89.3%,完全缓解率14.3%;其中25例有效患者治疗前血清VEGF水平为(326.00±33.67)ng/L,治疗后12周血清VEGF水平为(84.00±40.26)ng/L(P<0.01)。结论反应停联合VAD方案为治疗难治性复发性多发性骨髓瘤较好的选择,反应停可明显降低MM患者血清VEGF水平。
[Objectives] To evaluate the effectiveness of thalidomide combined with VAD chemotherapy in the treatment of the refractory and relapse multiple myeloma （MM）, and to test the levels of the serum VEGF of patient with MM before and after treatment with thalidomise. [Methods] 28 patients with the refractory and relapse MM were received the treatment of thalidomide which dosage was 400 -600 mg/d, combined with the standard VAD chemotherapy every five weeks and were tested the serum level of VEGF at 0 and 12 weeks after the treatment of thalidomide in the effective cases. [Results] Total effective rate was 89.3%, the rate of complete remission was 14,3%; Of the 25 response cases, the sVEGF levels were （326±33,67） ng/L before the treatment of thalidomide,these were （84±40,26） ng/L after 12 weeks respectively, The difference between before and after treatment of thalidomide showed a statistical significance （P 〈0,01）. [Conclusion] Thalidomide combined with VAD chemotherapy can be used as a better choice in the treatment of the refractory and relapse MM, it can obviously decrease the sVEGF levels in the patients with MM,
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2005年第24期3815-3817,共3页
China Journal of Modern Medicine
